Salanersen

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

Spinal Muscular AtrophyMuscular Atrophy, Spinal

14 competitors in Spinal Muscular Atrophy

#DrugCompanyPhaseTrials

1

Spinraza

Biogen

Approved

182

Evrysdi

Roche

Approved

73

Prilosec

DDexcel Pharma Technologies Ltd.

Approved

—4

Amondys 45

Sarepta Therapeutics

Approved

—5

Onasemnogene Abeparvovec

Novartis

Phase 3

76

Apitegromab

SScholar Rock, Inc.

Phase 3

47

Salanersen

Biogen

Phase 3

18

Taldefgrobep Alfa

BBiohaven Therapeutics Ltd.

Phase 3

19

Vesemnogene Lantuparvovec

LLantu Biopharma

Phase 3

210

NMD670

NNMD Pharma A/S

Phase 2

1Show 2 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Muscular Atrophy, Spinal2 trials

An Open-Label Study to Assess the Efficacy and Safety of Multiple Doses of Salanersen (BIIB115) Delivered Intrathecally to Treatment-Naïve, Presymptomatic Infants With Genetically Diagnosed Spinal Muscular Atrophy

Recruiting·Biogen·Phase 3·NCT07221669·30 enrolled

A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Efficacy of Salanersen (BIIB115) After Onasemnogene Abeparvovec Treatment in Infants With Genetically Diagnosed Spinal Muscular Atrophy

Recruiting·Biogen·Phase 3·NCT07444450·42 enrolled

Spinal Muscular Atrophy1 trial

A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety in Participants Aged 15 to 60 Years With Spinal Muscular Atrophy (SMA) Who Are Either New to SMA Treatment or Were Previously Treated With Risdiplam

Not yet recruiting·Biogen·Phase 3·NCT07444476·90 enrolled

Details

Drug Info

Related News